140 related articles for article (PubMed ID: 6238805)
41. Subdermal norethindrone pellets -- a method for contraception?
Odlind V; Moo-Young AJ; Gupta GN; Weiner E; Johansson ED
Contraception; 1979 Jun; 19(6):639-48. PubMed ID: 487813
[TBL] [Abstract][Full Text] [Related]
42. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
[TBL] [Abstract][Full Text] [Related]
43. Ovulation inhibition following vaginal administration of pills containing norethindrone and mestranol.
Coutinho EM; Silva AR; Carreira C; Barbosa I
Contraception; 1984 Feb; 29(2):197-202. PubMed ID: 6723313
[TBL] [Abstract][Full Text] [Related]
44. Effects of low dose oral contraceptives containing norethindrome and ethinyl estradiol on serum levels of progesterone and pituitary gonadotropins.
McGuire JL; Bariso CD; Yuliano E; Hume RJ; Pasquale SA
Contraception; 1975 Mar; 11(3):329-38. PubMed ID: 1116369
[TBL] [Abstract][Full Text] [Related]
45. Intranasal LHRH agonist treatment for inhibition of ovulation in women: clinical aspects.
Bergquist C; Nillius SJ; Wide L
Clin Endocrinol (Oxf); 1982 Jul; 17(1):91-8. PubMed ID: 6811167
[TBL] [Abstract][Full Text] [Related]
46. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
Garzo VG; Liu J; Ulmann A; Baulieu E; Yen SS
J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
[TBL] [Abstract][Full Text] [Related]
47. Luteinizing hormone releasing hormone agonist for contraception in breast feeding women.
Fraser HM; Dewart PJ; Smith SK; Cowen GM; Sandow J; McNeilly AS
J Clin Endocrinol Metab; 1989 Nov; 69(5):996-1002. PubMed ID: 2507572
[TBL] [Abstract][Full Text] [Related]
48. Luteinizing hormone-releasing hormone (LHRH) and its analogs for contraception in women: a review.
Thau RB
Contraception; 1984 Feb; 29(2):143-62. PubMed ID: 6426857
[TBL] [Abstract][Full Text] [Related]
49. [Peptid contraception--new principles for family planning].
Nillius SJ
Lakartidningen; 1981 Aug; 78(34):2845-8. PubMed ID: 7033692
[TBL] [Abstract][Full Text] [Related]
50. Gonadotropin-releasing hormone agonist-induced ovarian hyperstimulation: low-dose side effects in women and monkeys.
Navot D; Rosenwaks Z; Anderson F; Hodgen GD
Fertil Steril; 1991 Jun; 55(6):1069-75. PubMed ID: 1828042
[TBL] [Abstract][Full Text] [Related]
51. Contraception with subdermal implants releasing the progestin ST-1435: a dose-finding study.
Haukkamaa M; Laurikka-Routti M; Heikinheimo O; Moo-Young A
Contraception; 1992 Jan; 45(1):49-55. PubMed ID: 1591921
[TBL] [Abstract][Full Text] [Related]
52. Contraceptive properties of luteinising hormone releasing hormone.
Lambe RF; Werner-Zodrow I; Darragh A; Mall-Häfeli M
Lancet; 1979 Oct; 2(8146):801. PubMed ID: 90901
[TBL] [Abstract][Full Text] [Related]
53. New knowledge in the physiology of hormonal contraceptives.
Lobo RA; Stanczyk FZ
Am J Obstet Gynecol; 1994 May; 170(5 Pt 2):1499-507. PubMed ID: 8178898
[TBL] [Abstract][Full Text] [Related]
54. Failure to induce early abortion by huge doses of a superactive LRH agonist in women.
Skarin G; Nillius SJ; Wide L
Contraception; 1982 Nov; 26(5):457-63. PubMed ID: 6819111
[TBL] [Abstract][Full Text] [Related]
55. Variable ovarian response to gonadotropin-releasing hormone antagonist-induced gonadotropin deprivation during different phases of the menstrual cycle.
Fluker MR; Marshall LA; Monroe SE; Jaffe RB
J Clin Endocrinol Metab; 1991 Apr; 72(4):912-9. PubMed ID: 2005218
[TBL] [Abstract][Full Text] [Related]
56. Luteal contraception.
Yen S; Garzo G; Liu J
Contraception; 1987; 36 Suppl():13-25. PubMed ID: 2824125
[TBL] [Abstract][Full Text] [Related]
57. Gonadotrophin-releasing hormone agonists for new approaches to contraception in man.
Nillius SJ
Wien Klin Wochenschr; 1985 Dec; 97(23):865-73. PubMed ID: 3934848
[TBL] [Abstract][Full Text] [Related]
58. Combined use of clomiphene and intranasal luteinizing hormone-releasing hormone for induction of ovulation in chronically anovulatory women.
Phansey SA; Barnes MA; Williamson HO; Sagel J; Nair RM
Fertil Steril; 1980 Nov; 34(5):448-51. PubMed ID: 7002630
[TBL] [Abstract][Full Text] [Related]
59. Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment.
Carr BR; Parker CR; Madden JD; MacDonald PC; Porter JC
J Clin Endocrinol Metab; 1979 Sep; 49(3):346-9. PubMed ID: 224073
[TBL] [Abstract][Full Text] [Related]
60. Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N; Bastide A
Fertil Steril; 1987 Jan; 47(1):60-6. PubMed ID: 2947818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
